Although the beneficial effects of GIPR agonism appear to be attenuated in the hyperglycaemic conditions seen in patients with type 2 diabetes,63 even when administered at supraphysiological levels,64, 65 the impaired insulinotropic effect of GIP seems to be fully recoverable following a period of normalised plasma glucose levels.66 This suggests a role for co‐agonism with GLP‐1, utilising its glucose lowering effects to induce improvement in glycaemia that is enough to enable GIP to exert its insulinotropic effects and synergistically improve glucose levels further. The gene discussed is GCG; the disease is type 2 diabetes mellitus.